List view / Grid view

Issue 3 2009

Filter the results

 

article

Quantitative Proteomics for Systems Biology

29 May 2009 | By

The pharmaceutical industry continues to experience a high attrition rate during the latter stages of small molecule therapeutic development, most disappointingly during the late, and highly expensive stages of Phase II and Phase III trial1. If left unchecked, it is likely that this late-stage failure in drug development will only…

article

Article 3: qPCR Assay Design

29 May 2009 | By

Real-time PCR (qPCR) data are reliable only if they result from a robust qPCR assay that has been carefully designed, validated and optimised. This process requires an extensive assay design procedure aimed at generating an optimum primer/probe/amplicon combination to allow accurate quantification of nucleic acids with minimum need for post-PCR…

article

Cellular reprogramming and its implications for therapeutic applications

29 May 2009 | By

Nearly fifty years ago, it was hypothesised that terminally differentiated cells such as fibroblasts could be forced to take on a pluripotent state, similar to the embryonic stem cells (ES cells). The basis of the concept is the observation that all cell types, with minor exceptions, have the same genetic…

article

Addressing unmet needs

29 May 2009 | By

Joydeep Goswami from Invitrogen, who provide essential life science technologies for disease research, drug discovery, and commercial bioproduction, talks to us about current and future developments at the company.

article

High Content Analysis Roundtable

29 May 2009 | By

1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…